Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma Inc. : - XTANDI Approved by China NMPA for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer

11/09/2020 | 09:25am EDT

TOKYO - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas') today announced that the China National Medical Products Administration (NMPA) has approved XTANDI (enzalutamide soft capsules) for the treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) with high risk of metastasis.

This is the second approved indication in China for enzalutamide, which is already available for adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT), in whom chemotherapy is not yet indicated.

The approval is based on results from the PROSPER trial, a double-blind, placebo-controlled, pivotal Phase 3 trial that evaluated enzalutamide plus ADT versus placebo plus ADT in 1,401 men with nmCRPC and rapidly rising prostate-specific antigen levels. PROSPER met its primary endpoint of metastasis-free survival (MFS), with a median MFS of 36.6 months for men who received enzalutamide plus ADT, compared to 14.7 months with placebo plus ADT. Results demonstrated a 71 percent reduction in the risk of radiographic progression or death in men who received enzalutamide plus ADT, compared to placebo plus ADT (hazard ratio=0.29 [95% confidence interval: 0.24-0.35]; p

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about ASTELLAS PHARMA INC.
09/27SEAGEN : Urothelial Cancer Drug Padcev Gets Japanese Regulator's Approval
MT
09/27ASTELLAS PHARMA : Japan's MHLW Approves PADCEV (enfortumab vedotin) for Advanced Urothelia..
PU
09/27ASTELLAS PHARMA : Japan's MHLW Approves PADCEV« (enfortumab vedotin) for Advanced Urotheli..
BU
09/23ASTELLAS PHARMA : Tohoku University and Astellas Establish Second Phase of Comprehensive I..
PU
09/23ASTELLAS PHARMA INC. : will present 12-week results (S-13) from the pivotal Phase 3 SKYLIG..
AQ
09/22Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic..
AQ
09/22Astellas to Present Fezolinetant 12-Week Findings from Phase 3 SKYLIGHT 2Ö Trial in Ora..
CI
09/22ASTELLAS PHARMA : to Present Fezolinetant 12-Week Findings from Phase 3 SKYLIGHT 2™ ..
PU
09/21ASTELLAS PHARMA : Science-based Exercise at Home with Fit-eNce HomeTM Pilot Sales Begins T..
PU
09/20ASTELLAS PHARMA : ' and Pfizer's XTANDI« (enzalutamide) Reduced Risk of Death by 34% in Me..
PU
More news
Financials
Sales 2022 1 325 B 11 902 M 11 902 M
Net income 2022 194 B 1 747 M 1 747 M
Net cash 2022 478 B 4 290 M 4 290 M
P/E ratio 2022 17,7x
Yield 2022 2,67%
Capitalization 3 474 B 31 313 M 31 211 M
EV / Sales 2022 2,26x
EV / Sales 2023 1,90x
Nbr of Employees 15 455
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 875,00 JPY
Average target price 2 451,54 JPY
Spread / Average Target 30,7%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.17.63%31 313
JOHNSON & JOHNSON3.68%429 542
ROCHE HOLDING AG9.24%319 352
PFIZER, INC.19.37%244 283
NOVO NORDISK A/S48.08%227 557
ELI LILLY AND COMPANY34.09%205 250